Intervention Protocol

Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis

  1. Wenjuan Li1,
  2. Jing Zhang2,
  3. Liangzhi Xu1,*,
  4. Liulin Tang1,
  5. Xin Pan3,
  6. Taixiang Wu4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 20 FEB 2014

DOI: 10.1002/14651858.CD010977

How to Cite

Li W, Zhang J, Xu L, Tang L, Pan X, Wu T. Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010977. DOI: 10.1002/14651858.CD010977.

Author Information

  1. 1

    West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

  2. 2

    West China Second University Hospital, Sichuan University, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

  3. 3

    The University of Newcastle, Mother and Baby Center, School of Medicine and Public Health, New Castle, New South Wales, China

  4. 4

    West China Hospital, Sichuan University, Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, Chengdu, Sichuan, China

*Liangzhi Xu, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 17, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. liangzxu@126.com.

Publication History

  1. Publication Status: New
  2. Published Online: 20 FEB 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To estimate the clinical benefits and harms of all SERMs for postmenopausal osteoporosis in both prevention (women without postmenopausal osteoporosis) and treatment (postmenopausal osteoporosis with or without clinical history of previous osteoporotic fractures).

The principle objective of this review is based on the following questions:

  1. Is the use of SERMs effective and safe for the prevention and treatment of postmenopausal osteoporosis?
  2. Are SERMs more effective and safer than other approved drugs for prevention and treatment of postmenopausal osteoporosis?
  3. Which type of SERMs is the most effective or safest?